New drug approved for the treatment of Hepatitis C

The European Commission has approved the use of Gilead Sciences Inc's high-profile new hepatitis C drug Sovaldi  across the European Union.

The expected approval followed a positive recommendation from the European Medicines Agency in November.

According to Reuters, the once-a-day pill, also known as sofosbuvir, is the first approved to treat certain types of hepatitis C infection without the need for interferon, an injected drug that can cause severe flu-like symptoms.

0 comments:

Post a Comment

Subscribe to: Post Comments (Atom)